Onkopedia Leitlinienportal
45
Quality Score
Emerging
Onkopedia Leitlinienportal
by DGHO
Low confidence
✍️ Bumetric analysis
“
Onkopedia Leitlinienportal is an iOS app from DGHO in the Education category, currently rated 3.9★ across 14 ratings. Initial signal reads as no scraped reviews yet: judgment based on metadata only.
Quality Score is 45: Emerging (early traction worth watching). For a Education app, that means early traction worth watching. The full BU Investment Matrix below scores 8 dimensions including monetisation, growth, and operational risk.
Track changes month-over-month in the Performance section below: live snapshot history and revenue forecast included.
💰 Monthly revenue · now vs forecast
● Right now
$500
per month
→
12-mo forecast
$437 – $1575
per month
→
24-mo forecast
$405 – $3644
per month
INDIE tier
💡 Grow this revenue
Free AI audit of this app’s store listing
- Title & subtitle keyword fit
- Description hook & conversion structure
- Screenshots, ratings, reviews strategy
Typical impact: +2-5× organic installs
📊 Performance Tracking LIVE
5 snapshots on record
Rating
3.9
Reviews
14 reviews
Forecast Revenue / mo
$500
Snapshots tracked
5
since Mar 2026
ONE-TIME · BUILD
💰 Estimated build cost
$110K
↳ What it cost to build · not monthly revenue
Likely range $80K – $150K
$25K · MVP floor
$100K · indie scale
$500K+ · studio build
📈
Slow ROI — current MRR is well below build cost
Synthetic estimate. Inputs: category complexity, file size, screen count, monetization layer, platform reach, age × team-size proxy. Calibrated against 2024-2026 indie-agency rate surveys. Full math + source list on /methodology.
Where the money goes
| 🧱 MVP baseline (design + 1-store ship) | +$28K |
| 📱 5 unique screens × $4.5K | +$22K |
| ⚙ Education complexity ×1.20 | +$10K |
| ⚙ 8.0y maintenance × ~1-person team | +$47K |
Total estimate
$110K
ONE-TIME · EXIT VALUE
💵 Estimated acquisition value
$10K
↳ What it would sell for · not monthly revenue
Marketplace range $5K – $10K · 16× MRR multiple
💸
~0.1× build cost (under-water)
Synthetic estimate. Multiple band derived from ad-supported + age, rating quality, category demand, and user-base maturity. Calibrated against 2024-2026 indie-app-marketplace closed-deal medians. Full math + comparable deal list on /methodology.
How the multiple was built
| 📺 Ad-supported base | 15× MRR |
| 📅 8.0y proven track record | +20% |
| ⭐ ★ rating 3.5-4.0 (mixed) | -8% |
| 🏷 Education category multiple | +6% |
| ⭐ Small user base (<1K ratings) | -8% |
Final multiple
16× MRR
🛠 Estimated tech stack
🍎
Native iOS (Swift / UIKit)
Medium confidence · 70%
Also possible
Flutter
Heuristic guess from app bundle size, category, store description signals, and release-date stack era. Bumetric does not disassemble binaries — for binary-level certainty you would need an SDK intelligence tool or the manifest itself. Reasoning chain on the right. Full ruleset on /methodology.
Signals we read
| 📦 App bundle size | 36 MB |
| 🏷 Category context | Education |
| 📦 Small-mid iOS bundle | → Native Swift / UIKit (pre-2020 era) |
💀 Maintenance status
At risk
40%
Last shipped 2026-05-05 · 142 days ago
0 · Active
50 · At risk
100 · Abandoned
Heuristic risk score from time-since-last-update + ratings velocity proxy + Editor's Choice / curated featuring signals. Calibrated against 2024-2025 app-store ranking decay reports. Not a guarantee — a quiet app with a healthy codebase looks the same as an abandoned one until something breaks. Full math on /methodology.
Risk signals
| 📅 4 months since last update | Slowing cadence |
| 👥 Small user base (14 ratings) + 8.0y old | +10% (solo-project pattern) |
Verdict
At risk
🔬
How we forecast this revenue
LOW CONFIDENCEBaseline
$500/mo · ML-estimated from 234 triggers
Growth rate
+6.0% MoM · INDIE tier baseline (compound monthly)
Direction
Headwinds: rating drift may slow acquisition
6 months
$426 – $993
12 months
$437 – $1.6K
24 months
$405 – $3.6K
Compound growth at +6.0% MoM (tier baseline for INDIE). Range widens with horizon — typical noise band ±40% at 6mo.. Ranges widen with horizon — distant futures carry more uncertainty.
📊
BU Investment Matrix
Pre-traction · 38/100INDIE TIERlimited signalGrowth Velocity
5.0
Founder Strength
2.9
Product Quality
3.1
Revenue Strength
2.7
Monetization Maturity
1.0
Defensibility
4.0
Market Position
2.0
Operational Safety
10.0
- 💰 Revenue: Marginal — $200 - $1250/mo · INDIE tier · medium confidence, trajectory unclear.
- ⭐ Quality: 3.9★ across 14 reviews — weak — significant quality concerns.
- 📍 Market: Not yet charting in any of the 9 monitored markets.
- 📈 Growth: Insufficient signal to assess trajectory.
- ⚠️ Risk: Low — no material risk signals detected.
🎯 For competitors: Mixed picture. Worth competing if you have a clear UX or pricing edge — otherwise crowded segment.
💵 For acquirers: Estimated asking range 18-32× monthly = $9K-$16K.
Composite of 8 dimensions computed deterministically from public signals — no LLM, every score traces back to a measurable input. Default weights shown; "compete" / "acquire" / "invest" lenses re-weight without re-fetching.
Range:
💰 Forecast Revenue / mo
MODELRevenue forecast computed from BU's 234 trigger model on each snapshot. Calibrated against ground-truth from 58 verified-revenue apps.
🔬Forecast Breakdown — Why This Estimate?Top 4 of 4 triggers
Our ML model uses 200+ signals from public data. These are the most influential for this app:
| Established app (7y old)METRIC | +$800 | |
| Ad-supported / freemiumMETRIC | +$600 | |
| Single-language (English only)METRIC | −$400 | |
| Pre-traction phase (14 ratings)METRIC | −$300 |
METRIC = structural app data · REVIEW = mined from user reviews · ✓ VERIFIED = Stripe-verified anchor (TrustMRR)
📈 Reviews Growth
LIVECumulative review count from first BU snapshot. Each point = a tracked update.
⭐ Rating Trend
LIVEAverage rating evolution. Updates with each new review batch.
🆕 What's New · v3.4.1
Fehlerbehebung
Profile & Insights
Everything we know — and don't — about this app and its company.
Identification
- App name
- Onkopedia Leitlinienportal
- Developer
- DGHO
- Bundle ID
- Not found
- App Store URL
- Open in App Store
- Category
- Education
- Content rating
- 17+
- Languages
- EN
Company
- Website
- Not found
- Tagline
- Today
- Description
- Find apps and games for iPhone, iPad, Mac, and more on the App Store.
- Founded
- Not found
- HQ / Address
- Not found
- Employees
- Not found
- Logo
- Available
Revenue
- Reported revenue signal / mo
- Not found
- AI revenue estimate / mo
- Not found
- AI annual estimate
- Not found
- Model estimate / mo
- $500/mo
- Top-grossing rank
- Not found
- All-time revenue
- Not found
- Pricing
- Not found
Founder
Founder data not yet collected for this app.
Funding
Funding data not yet collected for this app.
Press & Links
Press & Links data not yet collected for this app.
Contacts & Socials
Contacts & Socials data not yet collected for this app.
🌍Geographic ReachNot ranked
This app is currently outside the top 100 grossing in all 9 countries we monitor (US, UK, DE, FR, JP, CA, AU, BR, IN). Niche or new apps often launch this way — popularity rankings appear once daily revenue clears the regional threshold.
Profile is built from iTunes Lookup + developer site scrape + ML revenue model. Empty fields show "Not found" — additional sources (Crunchbase, X, IndieHackers, Acquire.com) coming.
📝 About this app
Leitlinien zur Diagnostik und Therapie von Blut- und Krebserkrankungen - komprimiert, übersichtlich, aktuell und frei zugänglich.
Mit dem Internetportal Onkopedia hat die DGHO seit 2010 ein eigenes Instrument zur Erstellung und Veröffentlichung von Leitlinien etabliert. In Kooperation mit der OeGHO, der SGMO und der SGH+SSH werden hier Inhalte komprimiert, übersichtlich, aktuell und für jeden frei zugänglich präsentiert. Kostenpflichtig sind lediglich die erweiterten Leitlinien-Anhänge wie z.B. Studienergebnisse oder Therapieprotokolle.… View full description on the official store →
Mit dem Internetportal Onkopedia hat die DGHO seit 2010 ein eigenes Instrument zur Erstellung und Veröffentlichung von Leitlinien etabliert. In Kooperation mit der OeGHO, der SGMO und der SGH+SSH werden hier Inhalte komprimiert, übersichtlich, aktuell und für jeden frei zugänglich präsentiert. Kostenpflichtig sind lediglich die erweiterten Leitlinien-Anhänge wie z.B. Studienergebnisse oder Therapieprotokolle.… View full description on the official store →
App Specs
🔐 Own this app? Claim & verify MRR →💾 36 MB🔞 17+📱 iOS 15.0+🔖 v3.4.1🔄 updated 4mo ago🌐 EN📂 Education💰 Paid🚀 Launched 2018 (7y old)
📅
What Worked™ · Development Pipeline
3 EVENTS TRACKEDDetected changes in this app over its tracked lifetime — each event links cause (what changed) to effect (what moved). Sorted newest first.See full history →Version history →
2026-06
⭐
Rating ↑ 3.90 → 5.00 (improved 1.10★)
2026-06
🔄
Monetization changed: freemium → free
2026-03
🚀
First tracked snapshot — initial data captured
🌍
Multi-Country Performance
Available in 9 of 9 monitored markets| Market | Rating | Reviews | Current version |
|---|---|---|---|
| 🇦🇺 AU | 0★ | 0 | — |
| 🇧🇷 BR | 0★ | 0 | — |
| 🇨🇦 CA | 0★ | 0 | — |
| 🇩🇪 DE | 3.92857★ | 14 | 3.92857★ this version |
| 🇫🇷 FR | 0★ | 0 | — |
| 🇬🇧 GB | 0★ | 0 | — |
| 🇮🇳 IN | 0★ | 0 | — |
| 🇯🇵 JP | 0★ | 0 | — |
| 🇺🇸 US | 5★ | 1 | 5★ this version |
🔔
Track this app’s revenue
FREEGet an email when revenue moves by your threshold. No spam, unsubscribe in one click.
📝 Description
95
BU Score · Transcendent
Similar apps in Education
About this analysis
Why low confidence: only 14 ratings · no founder-verified revenue (model estimate only) · revenue figure is directional only.
📌 Final verdict — read this before you trust the numbers above
Onkopedia Leitlinienportal is a early-stage iOS app in the education space with weak public traction — only 14 ratings, no founder-verified MRR, and not ranked in any monitored grossing chart. The app appears to be monetised, but public signals are too sparse for a precise revenue estimate.
Bottom line: treat all revenue, audience and acquisition-value numbers on this page as directional only — not founder-verified facts.
❓ Frequently Asked Questions
7 answers · auto-generated from this app's public dataHow much does Onkopedia Leitlinienportal make per month?▴
Our model estimates Onkopedia Leitlinienportal earns roughly $500/mo, but with only 14 ratings the confidence interval is wide. No founder-verified MRR is available for this app, so this is a model output calibrated against comparable apps in the same category. See methodology for the formula.
What apps are like Onkopedia Leitlinienportal?▴
Browse the full Education category catalog to find similar apps with revenue, build cost, audience and tech stack data. Each /p/{slug} page also shows a Compare side-by-side widget with three peer apps from the same niche.
What is Onkopedia Leitlinienportal built with?▴
Our heuristic places Onkopedia Leitlinienportal on the Native iOS (Swift / UIKit) stack (Medium confidence, 70%). Signals: app bundle size, category context, store-description markers, release-date era. We don't disassemble binaries. Alternative possibilities: Flutter.
Is Onkopedia Leitlinienportal still actively maintained?▴
Maintenance status: At risk (40% abandonment risk). Last shipped version was 4 months ago. The risk score combines time-since-last-update with Editor's Choice / curated featuring + user-base maturity adjustments.
When was Onkopedia Leitlinienportal last updated?▴
Onkopedia Leitlinienportal last shipped a new version on 2026-05-05 — 4 months ago. This is the date Apple / Google last accepted a new build, not a content-only push.
Who makes Onkopedia Leitlinienportal?▴
Onkopedia Leitlinienportal is published by DGHO on the Apple App Store. See the full publisher portfolio (other apps by the same developer) via the More by developer block on the product page above.
What is Onkopedia Leitlinienportal's BU Score?▴
Onkopedia Leitlinienportal has a BU Score of 45/100 (Emerging). The score combines App Store rating, ratings count, monetization model and revenue signals calibrated against founder-verified MRR anchors. See the BU Score formula.